Abstract:Background The repetitive antigen stimulation during chronic infection often leads to the accumulation of CD8+CD57+ T cells. These cells express high levels of interferon-γ, granzyme B and perforin with elevated cytolytic effect, and are considered as the most potent cells for combating chronical viral infection. The status of CD8+CD57+ T cells in non-small cell lung cancer (NSCLC) has not been well defined. Methods We used flow cytometry and undertook a systemic approach to examine the frequency, immunophenotyping and functional properties of CD8+CD57+ T cells in the peripheral blood, tumor tissue and the corresponding normal tissue, as well as lung draining lymph nodes, of patients with NSCLC. Results CD57+ T cells expressed high levels of programmed cell death-1 (PD-1) in all tested compartments and were predominantly CD8+ T cells. These cells in the peripheral blood displayed a terminally differentiated phenotype as defined by loss of CD27 and CD28 while expressing KLRG1. CD8+CD57+ T cells exhibited enhanced cytotoxic potencies and impaired proliferative capability. Unlike CD57+ T cells in the peripheral blood, a significant proportion of CD57+ T cells in the primary tumors expressed CD27 and CD28. CD8+CD57+ T cells in tumors lacked cytotoxic activity. The proliferative activity of these cells was also impaired. CD8+CD57+ T cells in the corresponding normal lung tissues shared similarities with their counterparts in peripheral blood rather than their counterparts in tumors. The vast majority of CD8+CD57+ T cells in lung draining lymph nodes were positive for CD27 and CD28. These cells were unable to produce perforin and granzyme B, but their proliferative activity was preserved. CD8+CD57+ T cells in tumors displayed an inferior response to PD-1 blockade compared with their CD8+CD57- counterparts. Interleukin (IL)-15 preferentially restored the effector function of these cells. Additionally, IL-15 was able to restore the impaired proliferative activity of CD8+CD57+ T cells in tumors and peripheral blood. Conclusions Our data indicate that the failure of the immune system to fight cancer progression could be a result of impaired CD8+ T-cell functional maturation into fully differentiated effector T cells within the tumor microenvironment. Boosting IL-15 activity might promote tumor-reactive CD8+ T-cell functional maturation while preserving their proliferative activity.

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

A Reservoir of Stem-Like CD8 T Cells in the Tumor-Draining Lymph Node Maintains the Ongoing Anti-Tumor Immune Response

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells

Tumor Masses Support Naive T Cell Infiltration, Activation, and Differentiation into Effectors

A reservoir of stem-like CD8 + T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response

Tumor-Reactive CD8+ T Cells Enter a TCF1+PD-1- Dysfunctional State

Differentiation fate of a stem-like CD4 T cell controls immunity to cancer

Stem-like CD8+ T cells in cancer

Dendritic cells dysfunction in tumor-draining lymph nodes

CD8+ T cell states in human cancer: insights from single-cell analysis

Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer

The Primordial Differentiation of Tumor-Specific Memory CD8+ T Cells As Bona Fide Responders to PD-1/PD-L1 Blockade in Draining Lymph Nodes.

Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node

Dysfunction of Dendritic Cells in Tumor-Draining Lymph Nodes

CD8+CXCR5+ T Cells in Tumor-Draining Lymph Nodes Are Highly Activated and Predict Better Prognosis in Colorectal Cancer.

CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production

Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment

Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response

Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer

CD8+CD57+ T Cells Exhibit Distinct Features in Human Non-Small Cell Lung Cancer

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.